PF-07321332
Nirmatrelvir and ritonavir
PAXLOVID™
Development status
-
Emergency use/conditional marketing authorizations granted in multiple countries
-
Phase 3 clinical trials underway in Brazil, Chile, Colombia, Japan, Mainland China (sublicensed to Shenzhen Kangtai Biological Products), Peru, Russia, South Africa and U.S.
-
Korea Disease Control and Prevention Agency (KDCA) reviewing application for emergency use
34
active deals
Distribution
The vaccine is well-tolerated, easily distributed, storable at refrigerator temperatures and easily administered.
There is some concern about its efficacy, which is as low as 59.5% as per protocol and as high as 90% with a prime-boost regimen that is not included in the planned protocol. Data are lacking for older patients (>55 years).
